Financial Performance - The unaudited revenue of RMH Holdings Limited for the nine months ended 30 September 2023 was approximately S$2,250,000, representing a decrease of approximately S$169,000 or 7.0% compared to S$2,419,000 for the same period in 2022[8]. - The unaudited loss for the Group was approximately S$3,921,000 for the nine months ended 30 September 2023, a decrease of approximately S$1,579,000 or 28.7% from a loss of S$5,500,000 for the same period in 2022[8]. - Loss per share for the Company was approximately 0.31 Singapore cents for the nine months ended 30 September 2023, compared to 0.47 Singapore cents for the same period in 2022[8]. - The company reported a loss before taxation of S$3,921,000 for the nine months ended September 30, 2023, compared to a loss of S$5,500,000 in the same period of 2022, indicating an improvement of about 29%[94]. - The total comprehensive loss for the year to date was S$3,790,000, which includes an other comprehensive loss of S$131,000, highlighting ongoing challenges in financial performance[11]. - The company’s total comprehensive loss for the nine months ended September 30, 2023, reflects ongoing operational challenges and market conditions affecting profitability[11]. Revenue Breakdown - Dental services generated revenue of S$1,472,000 for the nine months ended September 30, 2023, with trading sales contributing S$778,000[86]. - Revenue from healthcare services was recognized entirely at a point in time, with no revenue recognized over time during the reporting period[86]. - Revenue from prescription and dispensing services is recognized when the patient obtains control of the medication and skincare products[78]. - Revenue from trading sales is recognized when control of the goods is transferred to the customer upon delivery[81]. - Revenue from aesthetic services, consultation services, treatment services, and trading sales, with performance obligations generally satisfied within one day[71][79][81]. Operating Expenses - Employee benefits expense decreased to S$2,011,000 for the nine months ended 30 September 2023 from S$2,396,000 in the same period in 2022[9]. - Other operating expenses decreased by approximately S$271,000 or 9.3%, from approximately S$2,910,000 for the nine months ended September 30, 2022 to approximately S$2,639,000 for the nine months ended September 30, 2023[144]. - The Group's cost of consumables and medical supplies used was approximately S$1,000,000 for the nine months ended September 30, 2023, down from approximately S$1,099,000 in 2022[123][127]. - Interest expenses on borrowings decreased to S$4,000 for the nine months ended September 30, 2023, down from S$14,000 in 2022, reflecting a reduction of approximately 71%[92]. Corporate Governance - The company complied with all applicable code provisions of the Corporate Governance Code during the nine months ended September 30, 2023[169]. - The board is committed to high standards of corporate governance to manage business risks and enhance transparency[168]. - The company will continue to review and improve its corporate governance practices[168]. - All directors confirmed compliance with the code of conduct regarding securities transactions throughout the nine months ended September 30, 2023[181]. Shareholder Information - The company did not recommend any dividend for the nine months ended September 30, 2023, consistent with the same period in 2022[102]. - The company has adopted a share option scheme, granting a total of 60,000,000 share options to ten directors and eligible participants at an exercise price of HK$0.109 per share[174]. - The total number of share options as of September 30, 2023, is 30,000,000, with 18,000,000 exercised and 12,000,000 lapsed[177]. - As of September 30, 2023, Brisk Success holds 210,024,000 shares, representing approximately 15.77% of the company's shareholding[165]. Strategic Focus - The core business operations are shifting towards dental implant services, with a two-year business development plan established in 2022[111][115]. - The Company sees significant market potential for dental implant services in mainland China, driven by a large population and aging demographics[112][115]. - The Group will focus resources on the continuous development of dental services and maintain a prudent investment strategy[113][115]. - The nature of the Group's main business has shifted from dermatology aesthetic services to dental care and dental implant services due to previous operational changes[118][119]. Compliance and Audit - The Audit Committee reviewed the unaudited condensed consolidated financial statements for the nine months ended September 30, 2023[194]. - The company established the Audit Committee on September 22, 2017, in compliance with GEM Listing Rules[193].
德斯控股(08437) - 2024 Q1 - 季度财报